-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PET/CT, the full name of "positron emission tomography/X-ray computed tomography", is a method of screening for early tumors throughout the body.
Screening can significantly improve the accuracy, sensitivity and specificity of diagnosis because it fuses PET images with CT images .
However, 18F-labeled PET scans are more sensitive than CT scans and 11 C-labeled choline PET scans.
Due to the poor sensitivity of traditional CT and bone scans to the staging of high-risk prostate cancer patients, researchers have been committed to investigating the effects of new PET-CT imaging.
Traditional CT and bone scans are not very sensitive to the staging of high-risk prostate cancer patients, so researchers have been investigating the effects of new PET-CT imaging.
EMPIRE-1 is a single-center, open-label phase 2/3 randomized controlled trial.
In the 18F-PET/CT group, the radiotherapy decision is strictly determined by the PET results, and the PET results are also used for target delineation.
Test procedure
Test procedureFrom September 18, 2012 to March 04, 2019, a total of 165 patients were randomly assigned, with a median follow-up time of 3.
The 3-year event-free survival rate in the traditional imaging group was 63.
In the adjusted analysis, the event-free survival rate in the PET/CT group was significantly increased (HR=2.
Event-free survival rate during follow-up of the two groups of patients
Event-free survival rate during follow-up of the two groups of patientsIt can be seen that incorporating 18F-PET/CT into the radiotherapy decision and plan after prostatectomy can significantly improve the survival rate without biochemical recurrence or persistence.
It can be seen that incorporating 18F-PET/CT into the radiotherapy decision and plan after prostatectomy can significantly improve the survival rate without biochemical recurrence or persistence.
references:
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
Leave a message here
